Neurochem Receives OK From ISRB to Continue Trial for Alzhemed

Neurochem's independent safety review board (ISRB) has issued a second recommendation to continue the company's North American Phase III clinical trial for Alzhemed, an investigational product candidate for the treatment of Alzheimer's disease.

Neurochem's ISRB for Alzhemed is made up of independent medical experts who monitor and evaluate the safety of patients taking part in the Alzhemed Phase III clinical trial in North America.

The recommendation by the ISRB members was based on their recent review of the safety data from 742 patients who have been treated with the medication for an average of 12 weeks. After reviewing the safety information, the ISRB concluded that the trial should continue as planned.